Impel Pharmaceuticals (IMPL) Short Interest Ratio & Short Volume

Short interest is the volume of Impel Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 851,500 shares of IMPL short. 10.79% of Impel Pharmaceuticals' shares are currently sold short. Learn More on Impel Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.79% of Impel Pharmaceuticals' floating shares are currently sold short.

Impel Pharmaceuticals saw a increase in short interest in November. As of November 30th, there was short interest totaling 851,500 shares, an increase of 2.1% from the previous total of 833,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Impel Pharmaceuticals currently has issued a total of 23,900,000 shares. Some of Impel Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Impel Pharmaceuticals currently has a public float of 7,890,000 shares.

10.79% of Impel Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Impel Pharmaceuticals: SciSparc Ltd. (24.15%), Biodexa Pharmaceuticals Plc (5.18%), Evelo Biosciences, Inc. (2.11%), Sunshine Biopharma, Inc. (0.77%), Comera Life Sciences Holdings, Inc. (2.38%), Aditxt, Inc. (0.99%), China SXT Pharmaceuticals, Inc. (4.78%), GRI Bio, Inc. (1.81%), Panbela Therapeutics, Inc. (2.36%), Allarity Therapeutics, Inc. (9.18%),

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($6.17 billion), Canadian Natural Resources Limited ($3.99 billion), T-Mobile US, Inc. ($3.78 billion), Charter Communications, Inc. ($3.37 billion), Coinbase Global, Inc. ($2.89 billion), Suncor Energy Inc. ($2.83 billion), Occidental Petroleum Co. ($2.64 billion), Tractor Supply ($2.31 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Rivian Automotive, Inc. ($1.71 billion). View all of the most shorted stocks.

Short selling IMPL is an investing strategy that aims to generate trading profit from Impel Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Impel Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMPL, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMPL, twice per month. The most recent reporting period available is November, 30 2023.